WHITEHOUSE, N.J. APRIL 17, 2019
Visikol announced today that it has been awarded $750,000 in National Science Foundation SBIR Phase II funding. Over the last three years, Visikol has been awarded several NIH and NSF SBIR grants which have led to the development and commercialization of key technologies for the company. These technologies include the Visikol® HISTO™ reagents which have been used by over 500 research labs as well as the 3Screen™ image analysis platform that has helped accelerate drug discovery programs for ten of the top twenty pharmaceutical companies.
“The purpose of this most recent grant award is to provide our team with additional resources to develop advanced image analysis tools. Specifically, we are using the funding to develop image analysis software that will leverage artificial intelligence to evaluate pathology data sets in order to identify toxicity liabilities,” described Visikol Computer Vision Scientist Alex Magsam.
To learn more about how Visikol is transforming tissues into quantitative and actionable insights, please reach out to the team at info@visikol.com or check out the Visikol service offering.